The FDA approved Sucampo Pharmaceuticals Inc.'s Amitiza (lubiprostone) for female patients with constipation-predominant irritable bowel syndrome (IBS-C), making it the only U.S.-approved drug for ...

AMITIZA is a chloride channel activator indicated for the treatment of CIC (24 mcg twice daily) in adults and for IBS-C (8 mcg twice daily) in women 18 years of age and older. Important Safety ...

announced Sunday the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA (lubiprostone) for the treatment of irritable bowel syndrome with constipation at ...

Most of the medications for constipation-predominant irritable bowel syndrome (IBS-C) are also used for chronic functional constipation, though there are some differences in how they’re used. In both ...

Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal conditions you can get. It’s defined as abdominal pain or discomfort with, ahem, “altered” bowel habits over a period of time.

Sucampo is smartly leveraging AMITIZA to increase its revenue via label expansion. Cobiprostone drugs under development could offer treatment for unmet medical needs. Acquisition of R-Tech Ueno is ...

DEAR DR. ROACH: I’m a young adult male who has been diagnosed with irritable bowel syndrome with constipation (IBS-C). Until this diagnosis, I had never even heard of the condition. A colonoscopy and ...

Dear Dr. Roach: I'm a young adult male who has been diagnosed with irritable bowel syndrome with constipation (IBS-C). Until this diagnosis, I had never even heard of the condition. A colonoscopy and ...

DEAR DR. ROACH: My wife is 51 and has generally struggled with constipation for as long as I’ve known her (many decades). Several weeks ago, an extended period without bowel movements began. She ...

BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Abbott (NYSE: ABT) today announced the availability of AMITIZA ® (lubiprostone) in Japan, a prescription medicine ...